Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT03338426 Completed - Clinical trials for Essential Hypertension, Dyslipidemia

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

FIESTA
Start date: January 15, 2018
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.

NCT ID: NCT03261375 Completed - Hypertension Clinical Trials

To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension

Start date: January 19, 2021
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, randomized sham-controlled trial to evaluate safety and efficacy of a multi-electrode radiofrequency renal denervation system (Netrod® System) in treating patients with uncontrolled essential hypertension.

NCT ID: NCT03258489 Completed - Healthy Volunteers Clinical Trials

Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients

Start date: July 20, 2018
Phase: N/A
Study type: Interventional

Hypertension is considered a serious public health problem. The imbalance in autonomic nervous system (ANS) activity is one of the main triggers in the development and maintenance of hypertension. The non-pharmacological management of this disease is an important resource, especially in refractory hypertensive patients or in hypertensive crises, where the pharmacological treatment does not present an efficient response. It is known that transcutaneous electrical nerve stimulation (TENS) is capable of modifying the autonomic balance, however, the effects of Interferential electrical stimulation (IES) on this system in normotensive and hypertensive volunteers are not yet known. These electrotherapeutic resources may be a non-pharmacological tool supporting the management of hypertension. The objective of this research is to study the effects of different TENS and IC parameters on cardiovascular variables of normotensive volunteers and hypertensive patients.

NCT ID: NCT03246555 Completed - Clinical trials for The Elderly (= 70 Years) With Essential Hypertension

Fimasartan in the Senior Subjects

FITNESS
Start date: July 15, 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.

NCT ID: NCT03156842 Completed - Dyslipidemia Clinical Trials

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

FIRST
Start date: May 29, 2017
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.

NCT ID: NCT02944734 Completed - Clinical trials for Essential Hypertension

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

NCT ID: NCT02938910 Completed - Healthy Clinical Trials

Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism

COEURALDO
Start date: November 2012
Phase: N/A
Study type: Observational

Animal models have demonstrated the role of aldosterone in left ventricular remodeling involving fibrosis, apoptosis and hypertrophy. Myocardial fibrosis is a risk factor for serious arrhythmia and sudden death in ischemic and idiopathic hypertrophic heart disease. It is accepted that patients with primary aldosteronism have a higher prevalence of LV hypertrophy , arterial involvement and increased cardiovascular risk. In humans, a link has been demonstrated between aldosterone and heart failure as well as the benefit of the administration of an anti -aldosterone drug to lower mortality in this population , regardless of blood pressure level . The administration of spironolactone ( aldosterone ) in hypertensive rats has prevented the occurrence of aortic fibrosis . Plasma aldosteronism in humans has been associated with inflammation, fibrosis and aortic stiffness . However, primary aldosteronism is generally associated with so-called secondary hypertension . Chronic hypertension alone is a recognized etiological factor of myocardial hypertrophy ( myocardial fibrosis very advanced ) . The purpose of this study is to investigate the effects of MRI hyperaldosteronism on the heart.

NCT ID: NCT02890173 Completed - Clinical trials for Essential Hypertension

Study of CS-3150 in Patients With Essential Hypertension

ESAX-HTN
Start date: September 2016
Phase: Phase 3
Study type: Interventional

To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.

NCT ID: NCT02848170 Completed - Clinical trials for Essential Hypertension

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Start date: August 2016
Phase: N/A
Study type: Interventional

Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.

NCT ID: NCT02839382 Completed - Clinical trials for Cardiovascular Disease

The Northwest Coalition for Primary Care Practice Support

H2N
Start date: May 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this project is to build capacity for quality improvement (QI) in small primary care practices across Washington, Oregon and Idaho by improving risk factors for heart attacks such as blood pressure, cholesterol and smoking. The Northwest Coalition for Primary Care Practice Support will assist practices by providing them with a QI coach, creating group learning opportunities, and conducting educational outreach activities. An innovative study design will be used to determine what levels and types of support are most helpful and effective.